Circulation Journal
Late Breaking Clinical Trials (JCS 2016)
Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension – Insights From the IBUKI and AIR Studies –
Tsutomu SajiMasafumi MyoishiKoichiro SugimuraNobuhiro TaharaYutaka TakedaKeiichi FukudaHorst OlschewskiYoshimi MatsudaSylvia NikkhoToru Satoh
Author information
JOURNALS FREE ACCESS FULL-TEXT HTML

Volume 80 (2016) Issue 4 Pages 835-842

Details
Full Text-HTML Download PDF (776K) Contact us
Abstract

Background:Inhaled iloprost is approved for pulmonary arterial hypertension (PAH) in many countries. IBUKI was a phase III, non-randomized, open-label study of the efficacy and safety of inhaled iloprost in Japanese patients with PAH.Methods and Results:Adults with PAH who were treatment-naïve or administered endothelin receptor antagonists (ERAs) and/or phosphodiesterase type 5 inhibitors (PDE5-Is) and in NYHA/WHO functional class (FC) III/IV had inhaled iloprost (2.5 µg, increased to 5.0 µg if tolerated) 6–9 times daily for 12 weeks. Eligible patients entered a 40-week extension phase. Endpoints included change from baseline to week 12 in pulmonary vascular resistance (PVR; primary endpoint), other efficacy parameters, and safety. Data were compared with new subgroup analyses of treatment-naïve Western PAH patients from the global phase III AIR study. 27 patients received iloprost: 89% were treated with an ERA and/or PDE5-I; 70% with both. At week 12, PVR improved from baseline by –124 dyn·sec·cm−5(95% CI, –177 to –72) and 6-min walking distance increased by 36.0 m (95% CI, 14.9 to 57.1). NYHA/WHO FC improved in 62%; none worsened. Common drug-related adverse events were headache (37%) and cough (15%); 1 patient experienced hypotension; none reported syncope or hemoptysis. There were no deaths and no unexpected long-term safety findings. AIR PAH subgroup analyses showed similar results.Conclusions:Inhaled iloprost appeared effective and safe in Japanese PAH patients, including ERA- and PDE5-I-treated patients, consistent with findings of the AIR PAH subpopulation and previous iloprost studies. (Circ J 2016; 80: 835–842)

Information related to the author
© 2016 THE JAPANESE CIRCULATION SOCIETY
Previous article Next article
feedback
Top